Log in to save to my catalogue

Safety, pharmacokinetics, and immunological activities of multiple intravenous or subcutaneous doses...

Safety, pharmacokinetics, and immunological activities of multiple intravenous or subcutaneous doses...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_plos_journals_1989018251

Safety, pharmacokinetics, and immunological activities of multiple intravenous or subcutaneous doses of an anti-HIV monoclonal antibody, VRC01, administered to HIV-uninfected adults: Results of a phase 1 randomized trial

About this item

Full title

Safety, pharmacokinetics, and immunological activities of multiple intravenous or subcutaneous doses of an anti-HIV monoclonal antibody, VRC01, administered to HIV-uninfected adults: Results of a phase 1 randomized trial

Publisher

United States: Public Library of Science

Journal title

PLoS medicine, 2017-11, Vol.14 (11), p.e1002435

Language

English

Formats

Publication information

Publisher

United States: Public Library of Science

More information

Scope and Contents

Contents

VRC01 is an HIV-1 CD4 binding site broadly neutralizing antibody (bnAb) that is active against a broad range of HIV-1 primary isolates in vitro and protects against simian-human immunodeficiency virus (SHIV) when delivered parenterally to nonhuman primates. It has been shown to be safe and well tolerated after short-term administration in humans; h...

Alternative Titles

Full title

Safety, pharmacokinetics, and immunological activities of multiple intravenous or subcutaneous doses of an anti-HIV monoclonal antibody, VRC01, administered to HIV-uninfected adults: Results of a phase 1 randomized trial

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_plos_journals_1989018251

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_plos_journals_1989018251

Other Identifiers

ISSN

1549-1676,1549-1277

E-ISSN

1549-1676

DOI

10.1371/journal.pmed.1002435

How to access this item